Browsing ODA Open Digital Archive by Author "Smith, Robert Løvsletten"
Now showing items 1-5 of 5
-
Effect of the NFIB rs28379954 T>C polymorphism on CYP2D6-catalyzed metabolism of solanidine
Smith, Robert Løvsletten; Wollmann, Birgit Malene Tovik; Størset, Elisabet; Lenk, Hasan Cagin; O'Connell, Kevin S.; Kringen, Marianne K.; Ingelman-Sundberg, Magnus; Molden, Espen (Peer reviewed; Journal article, 2024)Cytochrome P450 2D6 (CYP2D6) is important for metabolism of 20%–25% of all clinically used drugs. Many known genetic variants contribute to the large interindividual variability in CYP2D6 metabolism, but much is still ... -
Effects of a Novel UGT2B Haplotype and UGT1A4*3 Allele Variants on Glucuronidation of Clozapine In vivo
Smith, Robert Løvsletten; Wollmann, Birgit Malene Tovik; Kausberg, Marianne; Mæland, Sondre; Tveito, Marit; O'Connell, Kevin Sean; Molden, Espen; Kringen, Marianne K. (Current drug metabolism;Volume 23, Issue 1, Peer reviewed; Journal article, 2022)Background: Glucuronidation is an important metabolic pathway of clozapine (CLZ), but the impact of various uridine 5'diphospho-glucuronosyltransferases (UGT) polymorphisms on the exposure and metabolism of CLZ in vivo is ... -
Evidence for solanidine as a dietary CYP2D6 biomarker: Significant correlation with risperidone metabolism
Wollmann, Birgit Malene Tovik; Smith, Robert Løvsletten; Kringen, Marianne K.; Ingelman-Sundberg, Magnus; Molden, Espen; Størset, Elisabet (Peer reviewed; Journal article, 2023)Aims: The extensive variability in cytochrome P450 2D6 (CYP2D6) metabolism is mainly caused by genetic polymorphisms. However, there is large, unexplained variability in CYP2D6 metabolism within CYP2D6 genotype subgroups. ... -
Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients—a genome-wide association study adjusting for smoking habits
O`Connell, Kevin; Smith, Robert Løvsletten; Athanasiu, Lavinia; Djurovic, Srdjan; Kringen, Marianne K.; Molden, Espen; Andreassen, Ole Andreas (Translational Psychiatry; 10, Article number: 198 (2020), Journal article; Peer reviewed, 2020-06-19)Clozapine (CLZ) is the superior antipsychotic drug for treatment of schizophrenia, but exhibits an extensive interpatient pharmacokinetic variability. Here, we conducted a genome-wide association study (GWAS) of CLZ serum ... -
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype
Wollmann, Birgit Malene Tovik; Størset, Elisabet; Kringen, Marianne K.; Molden, Espen; Smith, Robert Løvsletten (Peer reviewed; Journal article, 2023)Purpose Poor metabolizers (PMs) of the highly polymorphic enzyme CYP2D6 are usually at high risk of adverse effects during standard recommended dosing of CYP2D6-metabolized drugs. We studied if the metabolism of solanidine, ...